BR112022025026A2 - Ensaio baseado em células para determinar atividade de morte tumoral in vitro de células imunitárias que expressam antigénio quimérico - Google Patents

Ensaio baseado em células para determinar atividade de morte tumoral in vitro de células imunitárias que expressam antigénio quimérico

Info

Publication number
BR112022025026A2
BR112022025026A2 BR112022025026A BR112022025026A BR112022025026A2 BR 112022025026 A2 BR112022025026 A2 BR 112022025026A2 BR 112022025026 A BR112022025026 A BR 112022025026A BR 112022025026 A BR112022025026 A BR 112022025026A BR 112022025026 A2 BR112022025026 A2 BR 112022025026A2
Authority
BR
Brazil
Prior art keywords
cell
immune cells
car
chimeric antigen
cells expressing
Prior art date
Application number
BR112022025026A
Other languages
English (en)
Inventor
Kendall Williams J
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112022025026A2 publication Critical patent/BR112022025026A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype

Abstract

ENSAIO BASEADO EM CÉLULAS PARA DETERMINAR ATIVIDADE DE MORTE TUMORAL IN VITRO DE CÉLULAS IMUNITÁRIAS QUE EXPRESSAM ANTÍGENO QUIMÉRICO. A presente invenção refere-se a um método in vitro para determinar a potência (por exemplo, citotoxicidade) de uma célula imunitária que expressa uma molécula de recetor de antigénio quimérico (CAR). Na amostra de teste, células imunes que expressam CAR são incubadas com células alvo que expressam um antígeno que interage com o CAR. Em uma amostra de controle, as células imunes que expressam CAR são incubadas com as células alvo e uma molécula inibidora que impede a interação entre o CAR e as células alvo. A quantidade de morte de células alvo é determinada tanto na amostra de teste quanto na amostra de controle e é comparada.
BR112022025026A 2020-06-08 2021-06-07 Ensaio baseado em células para determinar atividade de morte tumoral in vitro de células imunitárias que expressam antigénio quimérico BR112022025026A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063036249P 2020-06-08 2020-06-08
US202063125173P 2020-12-14 2020-12-14
PCT/IB2021/054996 WO2021250552A1 (en) 2020-06-08 2021-06-07 Cell-based assay for determining the in vitro tumor killing activity of chimeric antigen expressing immune cells

Publications (1)

Publication Number Publication Date
BR112022025026A2 true BR112022025026A2 (pt) 2023-02-14

Family

ID=76708258

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025026A BR112022025026A2 (pt) 2020-06-08 2021-06-07 Ensaio baseado em células para determinar atividade de morte tumoral in vitro de células imunitárias que expressam antigénio quimérico

Country Status (10)

Country Link
US (1) US20220057381A1 (pt)
EP (1) EP4162269A1 (pt)
JP (1) JP2023530238A (pt)
KR (1) KR20230022964A (pt)
CN (1) CN115917317A (pt)
AU (1) AU2021288751A1 (pt)
BR (1) BR112022025026A2 (pt)
CA (1) CA3186600A1 (pt)
MX (1) MX2022015611A (pt)
WO (1) WO2021250552A1 (pt)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
CA2398136A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
SG10201510092QA (en) 2010-12-09 2016-01-28 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013126720A2 (en) * 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing
EP2861622A4 (en) 2012-06-15 2016-06-01 Sinomab Bioscience Ltd Anti-idiotypic anti-CD22 antibodies and uses thereof
US9745368B2 (en) 2013-03-15 2017-08-29 The Trustees Of The University Of Pennsylvania Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US9701758B2 (en) 2013-05-24 2017-07-11 Board Of Regents, The University Of Texas System Anti-CD19 scFv (FMC63) polypeptide
PL3129470T3 (pl) 2014-04-07 2021-11-29 Novartis Ag Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
CN107108744B (zh) 2014-08-19 2020-09-25 诺华股份有限公司 抗cd123嵌合抗原受体(car)用于癌症治疗
WO2018111340A1 (en) * 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
CN110662771B (zh) * 2018-02-01 2023-07-28 南京驯鹿生物技术股份有限公司 一种结合bcma的嵌合抗原受体(car)及其应用
WO2020051345A1 (en) * 2018-09-05 2020-03-12 Memorial Sloan-Kettering Cancer Center Pleural effusion-based methods for assessing immunoresponsive cell activity

Also Published As

Publication number Publication date
CN115917317A (zh) 2023-04-04
MX2022015611A (es) 2023-04-18
AU2021288751A1 (en) 2023-02-09
CA3186600A1 (en) 2021-12-16
WO2021250552A1 (en) 2021-12-16
US20220057381A1 (en) 2022-02-24
KR20230022964A (ko) 2023-02-16
EP4162269A1 (en) 2023-04-12
JP2023530238A (ja) 2023-07-14

Similar Documents

Publication Publication Date Title
De Luca et al. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells
Fallarini et al. Expression of functional GPR35 in human iNKT cells
Ju et al. H2S-induced S-sulfhydration of pyruvate carboxylase contributes to gluconeogenesis in liver cells
Ames et al. The proteoglycan-like domain of carbonic anhydrase IX mediates non-catalytic facilitation of lactate transport in cancer cells
BR112018070823A2 (pt) anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno.
Houde et al. Intestinal epithelial cell differentiation involves activation of p38 mitogen-activated protein kinase that regulates the homeobox transcription factor CDX2
Byun et al. GSK3 inactivation is involved in mitochondrial complex IV defect in transforming growth factor (TGF) β1-induced senescence
Jarvis et al. Peroxiredoxin 1 functions as a signal peroxidase to receive, transduce, and transmit peroxide signals in mammalian cells
Li et al. Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E
Park et al. Hypoxia induces glucose uptake and metabolism of adipose‑derived stem cells
Tamura et al. AAA peroxins and their recruiter Pex26p modulate the interactions of peroxins involved in peroxisomal protein import
Luo et al. B7-H3 regulates lipid metabolism of lung cancer through SREBP1-mediated expression of FASN
Madeira et al. Human mesenchymal stem cell expression program upon extended ex-vivo cultivation, as revealed by 2-DE-based quantitative proteomics
Srivastava et al. Regulation of mitochondrial protein import by the nucleotide exchange factors GrpEL1 and GrpEL2 in human cells
Tarique et al. Plasmodium falciparum DOZI, an RNA helicase interacts with eIF4E
BR112017004773A2 (pt) biomarcadores para avaliar câncer de mama
BR112017025051A2 (pt) ensaio celular para detecção de homodímeros anti-cd3
BRPI0923199B8 (pt) método para determinar a presença de anticorpos de fixação de complemento
Mareddy et al. Proteomic profiling of distinct clonal populations of bone marrow mesenchymal stem cells
BR112022009290A2 (pt) Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70
Quach et al. Mild alkalization acutely triggers the Warburg effect by enhancing hexokinase activity via voltage-dependent anion channel binding
Kelley et al. Advanced aging causes diaphragm functional abnormalities, global proteome remodeling, and loss of mitochondrial cysteine redox flexibility in mice
Fong-Ngern et al. Prolonged K+ deficiency increases intracellular ATP, cell cycle arrest and cell death in renal tubular cells
Schibler et al. Mitochondrial-targeted decyl-triphenylphosphonium enhances 2-deoxy-D-glucose mediated oxidative stress and clonogenic killing of multiple myeloma cells
Nishida et al. Expression of adenosine A2b receptor in rat type II and III taste cells